Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of OncoVEX GM-CSF in stage IIIc/IV malignant melanoma
2006-003841-17Phase 2Completed
- Sponsor
- BioVex Group, Inc.
- Start
- Jan 2007
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of talimogene laherparepvec in melanoma, sponsored by BioVex Group, Inc. Primary endpoint: Tumor response rate. Started Jan 2007; status: completed.
02
Drugs
talimogene laherparepvec
03
Conditions
melanoma
Beyond the preview
Go deeper on 2006-003841-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003841-17.